Penumbra (PEN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Penumbra (PEN) reported $354.69 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 17.8%. EPS of $0.97 for the same period compares to $0.85 a year ago.The reported revenue represents a surprise of +4.12% over the Zacks Consensus Estimate of $340.66 million. With the consensus EPS estimate being $0.90, the EPS surprise was +7.78%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Penumbra performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Geographic Revenue- United States: $275.03 million versus the four-analyst average estimate of $265.01 million. The reported number represents a year-over-year change of +21.5%.Geographic Revenue- International: $79.66 million compared to the $76.07 million average estimate based on four analysts. The reported number represents a change of +6.6% year over year.Revenue- Embolization and Access - International: $35.23 million versus $33.32 million estimated by four analysts on average.Revenue- Thrombectomy - International: $44.43 million compared to the $42.74 million average estimate based on four analysts.Revenue- Embolization and Access - United States: $83.04 million versus $71.86 million estimated by four analysts on average.Revenue- Thrombectomy - United States: $191.99 million versus the four-analyst average estimate of $193.15 million.Revenue- Embolization and Access: $118.26 million versus $105.18 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +22.1% change.Revenue- Thrombectomy: $236.42 million compared to the $235.9 million average estimate based on four analysts. The reported number represents a change of +15.8% year over year.View all Key Company Metrics for Penumbra here>>>Shares of Penumbra have returned -5.6% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.Zacks Names #1 Semiconductor StockThis under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Penumbra, Inc. (PEN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks